Fig. 9From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyAdjusted mean change from baseline in A CDR-SB, B ADCOMS, and C ADAS-Cog14 during study 201 core, gap period, and OLE phase (OLE enrolled set excluding those who progressed beyond early AD). F/up = 90-day follow-up period following study 201 coreBack to article page